ERAL1 and breast carcinoma: With the exception of one study, which showed no effect of TCS on 17α-ethynylestradiol (EE2)-induced hERα activation in T47D-kbLuc breast cancer cell line [22], several in vitro studies have described TCS as anti-estrogenic in transactivation and proliferative assays using human cells [12,13,14].